



## **Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference**

January 6, 2022

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 am ET. Following the prepared remarks, Mr. Ganot will be available for Q&A.

Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by [clicking here](#). A webcast replay will be archived for approximately 30 days on the Events page.

### **About Solid Biosciences**

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit [www.solidbio.com](http://www.solidbio.com).

### **Investor Contact:**

David Carey  
FINN Partners  
212-867-1768  
[David.Carey@finnpartners.com](mailto:David.Carey@finnpartners.com)

Caitlin Lowie  
Solid Biosciences  
607-423-3219  
[clowie@solidbio.com](mailto:clowie@solidbio.com)

### **Media Contact:**

Erich Sandoval  
FINN Partners  
917-497-2867  
[Erich.Sandoval@finnpartners.com](mailto:Erich.Sandoval@finnpartners.com)



Source: Solid Biosciences Inc.